Literature DB >> 33454996

Biomarker levels in peri-implant crevicular fluid of healthy implants, untreated and non-surgically treated implants with peri-implantitis.

Diederik F M Hentenaar1, Yvonne C M De Waal2, Arjan Vissink1, Arie Jan Van Winkelhoff2, Henny J A Meijer1,2, Sylvia C Liefers3, Frans G M Kroese3, Gerry M Raghoebar1.   

Abstract

AIM: To compare biomarker levels in peri-implant crevicular fluid (PICF) of healthy implants with levels in PICF of implants with peri-implantitis (before and after non-surgical treatment).
MATERIALS AND METHODS: Samples were taken from 20 healthy implants (n = 17 patients) and from 20 implants with peri-implantitis (n = 19 patients) before and 3 months after non-surgical treatment using the Airflow Master Piezon® (EMS). A Luminex™ assay was used to evaluate pro-inflammatory and anti-inflammatory cytokines IL-1β, TNF-α, IL-6 and G-CSF, collagen degradation enzyme MMP-8, chemokines MCP-1 & MIP-1α/CCL3, bone markers OPG and sRANKL and interferon-γ. Clinical and radiographical characteristics were assessed. A Mann-Whitney U and Wilcoxon signed-rank test analysed between- and within-group differences.
RESULTS: IL-1β and MMP-8 levels were found significantly elevated in implants with peri-implantitis (p = .007; p = <.001, respectively). No difference in levels of TNF-α, IL-6, MCP-1 and MIP-1α/CCL3, OPG and G-CSF between healthy and diseased implants was found. Levels of sRANKL and INF-γ were under the level of detection. None of the biomarker levels improved after non-surgical therapy, and levels of IL-1β and MMP-8 remained high.
CONCLUSION: Implants diagnosed with peri-implantitis have higher levels of IL-1β and MMP-8 in PICF compared to healthy implants. Non-surgical therapy did not influence the inflammatory immune response.
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  biomarkers; crevicular fluid; multiplex immunoassay; non-surgical treatment; peri-implantitis

Mesh:

Substances:

Year:  2021        PMID: 33454996     DOI: 10.1111/jcpe.13423

Source DB:  PubMed          Journal:  J Clin Periodontol        ISSN: 0303-6979            Impact factor:   8.728


  6 in total

1.  Comparative Transcriptome Analysis of Gingival Immune-Mediated Inflammation in Peri-Implantitis and Periodontitis Within the Same Host Environment.

Authors:  Shasha Yuan; Cui Wang; Wenting Jiang; Yiping Wei; Qingqing Li; Zhanming Song; Siqi Li; Fei Sun; Zhongtian Liu; Ying Wang; Wenjie Hu
Journal:  J Inflamm Res       Date:  2022-05-25

2.  Bacterial-Specific Induction of Inflammatory Cytokines Significantly Decreases upon Dual Species Infections of Implant Materials with Periodontal Pathogens in a Mouse Model.

Authors:  Muhammad Imran Rahim; Andreas Winkel; Alexandra Ingendoh-Tsakmakidis; Stefan Lienenklaus; Christine S Falk; Michael Eisenburger; Meike Stiesch
Journal:  Biomedicines       Date:  2022-01-26

3.  The Characteristics of Microbiome and Cytokines in Healthy Implants and Peri-Implantitis of the Same Individuals.

Authors:  Lu Song; Jimin Jiang; Jia Li; Chuan Zhou; Yanqi Chen; Hongye Lu; Fuming He
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

Review 4.  Inflammasomes in Alveolar Bone Loss.

Authors:  Yang Li; Junqi Ling; Qianzhou Jiang
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

5.  Correlation between Peri-Implant Marginal Bone Loss Progression and Peri-Implant Sulcular Fluid Levels of Metalloproteinase-8.

Authors:  Renzo Guarnieri; Alessio Zanza; Maurilio D'Angelo; Dario Di Nardo; Andrea Del Giudice; Alessandro Mazzoni; Rodolfo Reda; Luca Testarelli
Journal:  J Pers Med       Date:  2022-01-06

6.  Peri-Implant Surgical Treatment Downregulates the Expression of sTREM-1 and MMP-8 in Patients with Peri-Implantitis: A Prospective Study.

Authors:  Glaucia Schuindt Teixeira Neves; Gayathiri Elangovan; Mayla Kezy Silva Teixeira; João Martins de Mello-Neto; Santosh Kumar Tadakamadla; Eduardo José Veras Lourenço; Daniel Moraes Telles; Carlos Marcelo Figueredo
Journal:  Int J Environ Res Public Health       Date:  2022-03-18       Impact factor: 4.614

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.